Reductions in Advanced Chronic Liver Disease Among People Who Inject Drugs: The ETHOS Engage Study
Liver International · 2026-12 · 46 (12)
DOI: 10.1111/liv.70940 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift Liver International, online erschienen am 30.10.2026. Verfasst von Anna Conway und 19 weiteren Autor:innen. Beteiligte Einrichtung: The Kirby Institute, University of New South Wales, Sydney, New South Wales, Australia. Hauptthemen laut MEDLINE: Substance Abuse, Intravenous, Antiviral Agents, Hepatitis C, Chronic. Die Arbeit nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Health and Medical Research Council, New South Wales Health Cepheid, Australian Department of Health.
Abstract (Originalsprache)
Background and Aims Liver disease is a significant risk for people who inject drugs due to the high burden of hepatitis C virus (HCV). There is limited data on the impact of the direct‐acting antiviral (DAA) therapy era on liver disease among people who inject drugs. This study evaluated baseline and longitudinal liver disease in a national cohort of people who inject drugs recruited over three Waves: 2018–2019, 2019–2021, and 2023–2025.
Methods
The ETHOS Engage Study is an observational cohort of people who inject drugs attending drug treatment clinics and needle and syringe programs in Australia. Participants completed a questionnaire and underwent point‐of‐care HCV RNA testing (Xpert HCV Viral Load Fingerstick) and liver stiffness measurement (LSM) by vibration‐controlled transient hepatic elastography (FibroScan). Advanced chronic liver disease was defined by LSM of 10 kPa or above.
Results
Among all enrolments with a valid LSM ( n = 3126, 79% recruited at drug treatment clinics), 11% had advanced chronic liver disease, decreasing from 12.0% (154/1287) in 2018–2019 to 7.9% (66/839) in 2019–2021, and 6.4% (62/967) in 2023–2025. In adjusted analyses, participants recruited between 2019–2021 and 2023–2025 were less likely to have advanced chronic liver disease (vs. 2018–2019; aOR 0.66, 95% CI: 0.48–0.90 and aOR 0.56, 95% CI: 0.40–0.77, respectively). Current HCV infection declined from 24% in 2018–2019 to 10% in 2023–2025. Among participants with LSM in more than one wave and current HCV infection at first visit and no current HCV infection at second visit ( n = 44), advanced chronic liver disease declined from 19% to 5%.
Conclusions
Unrestricted access to DAA therapies in Australia has been associated with reduced liver disease burden among people who inject drugs. Monitoring of liver health in this population is important, given potential ageing and non‐HCV liver disease impacts.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- The Kirby Institute, University of New South Wales, Sydney, New South Wales, Australia.
- Centre for Social Research in Health, University of New South Wales, Sydney, New South Wales, Australia.
- Centre for Epidemiology and Evidence, NSW Health, Sydney, New South Wales, Australia.
- Department of Health Systems and Populations, Macquarie University, Sydney, New South Wales, Australia.
- Epidemiology and Systems Branch, NSW Health, Sydney, New South Wales, Australia.
- Kirketon Road Centre, Sydney, New South Wales, Australia.
ORCID-Profile: Anna Conway, Heather Valerio, Jessie Payne, Alison D Marshall, Marianne Martinello, Shane Tillakeratne, Putu Novi Arfirsta Dharmayani, Phillip Read, Louisa Degenhardt, Annabelle Stevens, Jeremy Hayllar, Michael Christmass, Victoria Cock, Jason Grebely, Gregory J Dore
Förderung
- National Health and Medical Research Council
- New South Wales Health Cepheid
- Australian Department of Health
- National Institute of Health
- NHMRC
Zitieren
APA
Conway, A., Valerio, H., Payne, J., Silk, D., Marshall, A. D., Martinello, M., Tillakeratne, S., Dharmayani, P. N. A., Milat, A., Amin, J., Read, P., Degenhardt, L., Stevens, A., Hayllar, J., Christmass, M., Cock, V., Doumany, J., Grebely, J., Dore, G. J., & ETHOS Engage Study Group (2026). Reductions in Advanced Chronic Liver Disease Among People Who Inject Drugs: The ETHOS Engage Study. Liver International, 46(12). https://doi.org/10.1111/liv.70940
Vancouver
Conway A, Valerio H, Payne J, Silk D, Marshall AD, Martinello M, et al. Reductions in Advanced Chronic Liver Disease Among People Who Inject Drugs: The ETHOS Engage Study. Liver International. 2026;46(12). doi:10.1111/liv.70940
BibTeX
@article{Conway2026,
author = {Conway, Anna and Valerio, Heather and Payne, Jessie and Silk, David and Marshall, Alison D and Martinello, Marianne and Tillakeratne, Shane and Dharmayani, Putu Novi Arfirsta and Milat, Andrew and Amin, Janaki and Read, Phillip and Degenhardt, Louisa and Stevens, Annabelle and Hayllar, Jeremy and Christmass, Michael and Cock, Victoria and Doumany, Jessica and Grebely, Jason and Dore, Gregory J and ETHOS Engage Study Group, ETHOS Engage Study Group},
title = {Reductions in Advanced Chronic Liver Disease Among People Who Inject Drugs: The ETHOS Engage Study},
journal = {Liver International},
year = {2026},
volume = {46},
number = {12},
doi = {10.1111/liv.70940}
}
EUVIMED